Anticipated Generic Releases 2025

There are several brand name medications that will lose exclusivity in the first half of 2025 and have anticipated release dates of their generic formulation. Generic drugs are marketed after the expiry of a brand-name drug’s patent, offering affordable alternatives while maintaining the same efficacy and safety profiles. These dates below are estimated and are subject to change. Carlisle Medical will update our website once a generic formulation has been released into the market.

Namzaric is used for the treatment of moderate to severe Alzheimer disease and has an anticipated release date of January 2025.

Xarelto is a blood thinner used for the prevention of stroke or systemic embolism. It is often used after surgeries to prevent blood clots from forming which can lead to deep vein thrombosis or pulmonary embolism. Xarelto has an anticipated release date of March 2025.

Horizant is FDA approved for the management of postherpetic neuralgia (PHN) in adults. It is also used off-label to treat neuropathic pain. It has an anticipated release date of April 2025.

Brilinta is FDA approved to treat acute coronary syndrome, minor ischemic stroke, and coronary artery disease and has an anticipated release date of May 2025.

Nucynta is used for the treatment of pain, neuropathic pain and diabetic peripheral neuropathy. Nucynta is available in both an immediate release and extended release (ER) version. Current information shows the immediate release strengths of 50mg, 75mg, and 100mg have an anticipated release date of May 2025.